TO THE EDITOR Dermatomyositis (DM) is a rare systemic autoimmune disease characterized by inflammation of the skin and muscle. Skin rash in DM may precede the onset of muscle disease by months to years, and in some cases overt muscle disease may remain mild or never occur. DM skin disease manifests in varied ways including facial edema, pink to violaceous patches on the eyelids (heliotrope sign), violaceous scaly plaques with atrophy on the shoulders and hips, violaceous atrophic scaling papules on the interphalangeal joints (Gottron's papules), and prominent nailfold telangiectasias. However, these findings are variably present, and DM skin disease can share clinical features with cutaneous lupus, overlap connective tissue disease syndromes, UV light-induced reactions, and psoriasis (Sontheimer, 2002) , often creating diagnostic difficulty at early presentation.
Psoriasis is an inflammatory skin disease most commonly characterized by well-demarcated plaques with micaceous scales. Histopathologically, psoriasis displays epidermal acanthosis, confluent parakeratosis, subcorneal neutrophils, and thinning of the suprapapillary plate. In contrast, DM is characterized by an interface dermatitis with a superficial perivascular infiltrate, and dermal mucin deposition. However, DM patients often present with erythematous scaly plaques in the scalp or on extremities, which can be clinically confused with psoriasis. In addition, many skin biopsies of DM can actually show minimal to no interface dermatitis, and have evidence of neutrophilic inflammation (Ito et al., 1995; Caproni et al., 2004) , perivascular dermatitis, and even epidermal hyperplasia not dissimilar to that seen in psoriasis.
Molecular profiling has widely been used to aid the diagnosis of cancer patients since the publication of landmark work by Golub et al. (1999) . It has also been applied in autoimmune diseases such as systemic lupus erythematosus for similar purposes (Chaussabel et al., 2008) . In this report, we compare the molecular features of DM and psoriasis and apply molecular profiling to aid in the diagnosis of an ambiguous case of DM.
Our index case, a 32-year-old woman, presented in June 2005 with the 3-month onset of well-demarcated violaceous erythematous, scaling plaques on her elbows, extensor forearms, dorsal hands, lateral thighs, knees, and lower legs, concerning for either psoriasis or Gottron's sign of DM (Figure 1a -c). Diffuse erythema was also present on her scalp and periungual areas, but she did not display psoriatic nail changes, geographic tongue, or heliotrope sign. Antinuclear antibodies were positive (titer 1:2,560) with a homogenous pattern. Other antibodies including anti-Jo1, SSA, SSB, anti-dsDNA, and anti-centromere were negative. Given her clinical ambiguity, a biopsy of one of these psoriasis-like lesions on the knee was performed. The biopsy demonstrated regular epidermal acanthosis, parakeratosis, mild, superficial perivascular infiltrate, and dilated papillary dermal vessels consistent with psoriasis ( Figure 1d ). No interface dermatitis was detected. However, a colloidal iron stain revealed abundant mucin throughout the dermis (Figure 1e ), which is unusual in psoriasis and more consistent with DM. Given the inconclusive results from traditional histopathology, genome-wide expression analysis was applied to determine whether an investigation into the molecular nature of the lesion could aid in clinical diagnosis. All patients signed consent, and our study complied with the Declaration of Helsinki principles and was approved by the Stanford Institutional Review Board.
First, we compared the molecular differences between psoriasis and DM. Lesional skin biopsies were obtained from 34 DM and 33 psoriasis patients in an independent cohort (Yao et al., 2008) and subjected to one-way hierarchical clustering (based in individual genes but not samples) to identify the gene expression patterns that differentiated these disease processes (Supplementary Methods online). Both psoriasis and DM reveal strong activation of type I IFN and T-cell signaling pathways (Figure 2a and c; Caproni et al., 2004; Lew et al., 2004; Greenberg et al., 2005; Wenzel et al., 2006; Yao et al., 2008) . In addition, both diseases display a characteristic downregulation of genes involved in lipid metabolism (Gudjonsson et al., 2009; Pietrzak et al., 2010) . The pathways that distinguished DM from psoriasis included genes involved in mucin and extracellular matrix synthesis, complement components, and angiogenesis, which were upregulated specifically in DM (Scott and Arroyave, 1987) . Psoriasis, on the other hand, revealed an upregulation of genes involved in epidermal differentiation, proliferation, and antimicrobial response (Van de Kerkhof and Van Erp, 1996; de Jongh et al., 2005) , which agrees with the disease pathogenesis of psoriasis at the molecular level and also validates our approach. Next, we compared the molecular profile of the lesional skin of our patient with independent skin biopsies from confirmed DM and psoriasis patients. Our patient's lesion was obtained from a portion of the original biopsy submitted for histopathology taken from a psoriatic-appearing plaque on the knee. Two-way unsupervised hierarchical clustering demonstrated that the patient sample clustered within the DM samples, suggesting that, despite the equivocal histology, our patient's sample was molecularly more similar to DM than psoriasis (Figure 2b and c) . Principal components analysis, adjusted for any batch processing effects, also confirmed the molecular similarity of this patient to the DM patient population (Figure 2d) .
To understand which gene signaling pathways drove the clustering of our patient's biopsy with DM, we performed one-way hierarchical clustering (based on genes but not on samples), which allowed placement of the patient's expression data in the center of the dendrogram for easy comparison with the psoriasis (left) and DM (right) samples (Figure 2e ). The Pearson's correlation coefficient was calculated between our sample and the mean of both the psoriasis or DM gene expression values using a 100-gene moving window (Figure 2e) . Interestingly, the gene expression pattern was very similar among our patient, DM, and psoriasis over clusters 3, 5, 7, which had enrichment of genes involved in lipid metabolism, type I IFN pathway activation, and T-cell function (Figure 2f ). However, for clusters 1, 2, 4, and 6, our patient displayed gene expression patterns more consistent with DM than psoriasis. These clusters were enriched with genes involved in lipid metabolism, extracellular matrix synthesis, mucin synthesis, complement cascade, and angiogenesis. There was a cluster of genes involved in proliferation and cell cycle differentiation (cluster 8) where our patient showed molecular similarity to psoriasis. This observation is consistent with the increased epidermal thickness (and proliferation) seen on histology.
Four years after presentation, our patient developed proximal muscle weakness and dysphagia with corresponding elevation in creatine kinase and aldolase. Her electromyography showed evidence of chronic inflammatory proximal myopathy with active dennervation features. Her skin rash remained similar to initial presentation. Thus, she fulfilled four out of five criteria of Bohan and Peter (1975) (rash, elevated muscle enzymes, proximal weakness, and abnormal electromyography), confirming a diagnosis of DM. This case demonstrates the diverse ways in which DM can present, compares the molecular profile between psoriasis and DM, and highlights the utility of molecular profiling to aid in diagnosis where histopathologic criteria may be inconclusive.
